Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
| Autor: | Richard C. Reichman, Raphael Dolin, Angela Dexter, Peter Gerondelis, Lisa M. Demeter, Taimor Nawaz, Gene D. Morse |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_treatment Molecular Sequence Data Human immunodeficiency virus (HIV) Drug Resistance medicine.disease_cause Peripheral blood mononuclear cell Antiviral Agents Zidovudine immune system diseases parasitic diseases Immunology and Allergy Medicine Humans heterocyclic compounds In patient Didanosine Mutation Chemotherapy Acquired Immunodeficiency Syndrome Base Sequence business.industry virus diseases RNA-Directed DNA Polymerase biochemical phenomena metabolism and nutrition Virology Reverse transcriptase HIV Reverse Transcriptase Infectious Diseases HIV-1 Female business medicine.drug |
| Zdroj: | The Journal of infectious diseases. 172(6) |
| ISSN: | 0022-1899 |
| Popis: | Human immunodeficiency virus type 1 (HIV-1) isolates from 2 patients who received didanosine (ddI) monotherapy for > 2 years were analyzed for reverse transcriptase (RT) mutations by sequencing of proviral DNA from peripheral blood mononuclear cell cultures. One patient was otherwise antiretroviral-naive; the other had received zidovudine for 5 months before beginning ddI therapy. Isolates obtained from both patients before initiation of ddI monotherapy were free of HIV-1 RT mutations associated with zidovudine or ddI resistance. However, after prolonged ddI monotherapy, mutations associated with zidovudine resistance (M41L, D67N, K70R, and/or T215Y) were detected in HIV-1 isolates from both patients. There was no evidence that surreptitious use of zidovudine or technical artifact caused these findings. This observation suggests that prolonged ddI monotherapy may decrease the efficacy of subsequent zidovudine therapy in some patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|